Kenya has suspended operations at a United States-funded Ebola treatment centre in the western county of Kisumu, a move that underscores a shifting alignment in the country’s public health partnerships. The facility, established in 2018 as part of a bilateral agreement between Nairobi and Washington, had been a cornerstone of the region’s preparedness against viral haemorrhagic fevers.
Government sources confirmed the suspension late on Monday, citing a strategic reassessment of foreign health investments. The decision coincides with the rapid expansion of a British-backed vaccine initiative, led by the University of Oxford’s Jenner Institute, which has already reached 200,000 doses administered in Kenya’s eastern provinces.
The US centre, staffed by American epidemiologists and equipped with high-containment laboratories, had been praised by the World Health Organisation for its role in training local clinicians. Its closure not only represents a loss of operational expertise but also raises questions about the durability of Washington’s health diplomacy in East Africa.
A senior official at Kenya’s Ministry of Health, speaking on condition of anonymity, said the government was prioritising investments that offered “tangible, scalable outcomes” particularly in vaccine development. “The US centre was a static facility. The UK programme provides mobile vaccination teams and cold-chain logistics that reach communities beyond the hospital setting,” the official added.
Critics have accused Nairobi of playing aid partners off against each other. Dr. Amira Hassan, a public health analyst at the University of Nairobi, described the suspension as “a geopolitical gamble that could leave Kenya exposed if the UK programme encounters delays.”
The British initiative, formally the Kenya Vaccine Ecosystem Project, received £15 million from the Foreign, Commonwealth and Development Office in January. It aims to immunise 1.5 million people against Ebola and other haemorrhagic fevers by the end of 2026. The project’s success to date has been driven by community health workers and digital tracking systems, a model that Kenyan officials find more adaptable than the US centre’s fixed infrastructure.
Washington’s response has been measured. A spokesperson for the US Embassy in Nairobi stated: “We are disappointed but respect Kenya’s sovereign health choices. Our bilateral health cooperation continues in other areas.” However, US Senators on the Africa Subcommittee have privately expressed concern that the shutdown may embolden other nations to reassess American health investments.
The suspension comes at a delicate moment for Kenya’s health system. The country is still recovering from a surge in dengue fever cases last year, and its public hospitals rely heavily on external funding. The US centre was part of a network of five regional facilities designed to detect and contain outbreaks before they escalated.
Analysts suggest that Kenya’s decision reflects a broader trend among African nations to demand more tailored partnerships from Western donors. “Countries no longer want turnkey projects,” said Dr. James Kariuki, a former Kenyan ambassador to the WHO. “They want technology transfer, local manufacturing, and agile responses. The UK model offers that. The US model was stagnating.”
The UK’s success in Kenya may be linked to its flexible approach. The vaccine programme includes provisions for local production of mRNA vaccines, a capability that Kenyan officials believe will reduce dependence on foreign suppliers in future pandemics.
As the US centre sits dormant, its staff reassigned to other projects, the Kenyan government is expected to issue a formal policy paper on foreign health investments within the next month. The outcome will be closely watched by other nations seeking to balance diplomatic ties with practical public health outcomes.
For now, the suspension marks a clear pivot. Kenya’s health strategy is no longer anchored by bricks and mortar but by mobile units and syringes. The question remains whether this shift will prove resilient when the next outbreak strikes.
